132 related articles for article (PubMed ID: 29248731)
1. Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments.
Maltais R; Trottier A; Roy J; Ayan D; Bertrand N; Poirier D
J Steroid Biochem Mol Biol; 2018 Apr; 178():167-176. PubMed ID: 29248731
[TBL] [Abstract][Full Text] [Related]
2. Insight into the mode of action and selectivity of PBRM, a covalent steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
Trottier A; Maltais R; Ayan D; Barbeau X; Roy J; Perreault M; Poulin R; Lagüe P; Poirier D
Biochem Pharmacol; 2017 Nov; 144():149-161. PubMed ID: 28800957
[TBL] [Abstract][Full Text] [Related]
3. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
Ayan D; Maltais R; Roy J; Poirier D
Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
[TBL] [Abstract][Full Text] [Related]
4. An irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 inhibits estradiol synthesis in human endometriosis lesions and induces regression of the non-human primate endometriosis.
Poirier D; Nyachieo A; Romano A; Roy J; Maltais R; Chai D; Delvoux B; Tomassetti C; Vanhie A
J Steroid Biochem Mol Biol; 2022 Sep; 222():106136. PubMed ID: 35691460
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of 16β-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17β-ol as inhibitors of 17β-HSD1 and/or steroid sulfatase for the treatment of estrogen-dependent diseases.
Lespérance M; Roy J; Djiemeny Ngueta A; Maltais R; Poirier D
Steroids; 2021 Aug; 172():108856. PubMed ID: 33945801
[TBL] [Abstract][Full Text] [Related]
6. A Targeted-Covalent Inhibitor of 17β-HSD1 Blocks Two Estrogen-Biosynthesis Pathways: In Vitro (Metabolism) and In Vivo (Xenograft) Studies in T-47D Breast Cancer Models.
Poirier D; Roy J; Maltais R
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33924352
[TBL] [Abstract][Full Text] [Related]
7. siRNA-based breast cancer therapy by suppressing 17β-hydroxysteroid dehydrogenase type 1 in an optimized xenograft cell and molecular biology model in vivo.
Li F; Zhu Z; Xue M; He W; Zhang T; Feng L; Lin S
Drug Des Devel Ther; 2019; 13():757-766. PubMed ID: 30863015
[TBL] [Abstract][Full Text] [Related]
8. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
[TBL] [Abstract][Full Text] [Related]
9. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
[TBL] [Abstract][Full Text] [Related]
10. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
11. Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone.
Ngueta AD; Roy J; Maltais R; Poirier D
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677690
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
[TBL] [Abstract][Full Text] [Related]
13. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
[TBL] [Abstract][Full Text] [Related]
14. Lead optimization of 17β-HSD1 inhibitors of the (hydroxyphenyl)naphthol sulfonamide type for the treatment of endometriosis.
Henn C; Einspanier A; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
J Med Chem; 2012 Apr; 55(7):3307-18. PubMed ID: 22380653
[TBL] [Abstract][Full Text] [Related]
15. Estradiol-independent modulation of breast cancer transcript profile by 17beta-hydroxysteroid dehydrogenase type 1.
Aka JA; Calvo EL; Lin SX
Mol Cell Endocrinol; 2017 Jan; 439():175-186. PubMed ID: 27544780
[TBL] [Abstract][Full Text] [Related]
16. First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases.
Salah M; Abdelsamie AS; Frotscher M
J Med Chem; 2017 May; 60(9):4086-4092. PubMed ID: 28406629
[TBL] [Abstract][Full Text] [Related]
17. Chemical synthesis, characterisation and biological evaluation of lactonic-estradiol derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Farhane S; Fournier MA; Poirier D
J Steroid Biochem Mol Biol; 2013 Sep; 137():322-31. PubMed ID: 23685015
[TBL] [Abstract][Full Text] [Related]
18. Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for
Salah M; Tahoun M; Rudzitis-Auth J; Stotz L; van Koppen CJ; Laschke MW; Abdelsamie AS; Frotscher M
J Med Chem; 2023 Jul; 66(13):8975-8992. PubMed ID: 37369108
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives.
Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D
J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103
[TBL] [Abstract][Full Text] [Related]
20. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]